Product Image

Triple Strength Vitamin K-2 Menaquinine-7 150 mcg

4.8
★ ★ ★ ★ ★
(149 ratings)
Vitamin K 150 mcg
Product Image
Score78

A simple MK-7 supplement provides focused vitamin K2 support, with supplied record repeats the same K2 amount and creates dose ambiguity as the main trade-off.

How scoring works
Capsule
Quantity:30 VegCap(s) • (30 servings)
Goals:
Anti-Aging
Heart Health
Cardiovascular Support
Bone Health
General Health

Score 78

A simple MK-7 supplement provides focused vitamin K2 support, with supplied record repeats the same K2 amount and creates dose ambiguity as the main trade-off.

How scoring works
$21.09($0.70 per serving)
Vitacost
$ 21.09
iHerb
$ 21.09
Report prices

Analysis

MK-7 is a long-acting vitamin K2 form that supports activation of proteins involved in bone mineral use and calcium handling. The focused formula is easier to assess than a large multinutrient blend.

The a substantial daily amount is clearly aligned with dedicated K2 supplementation. The single active is easy to understand but premium-priced, although it does not supply vitamin D, calcium, or magnesium for broader bone support.

The supplied record repeats the same K2 amount and creates dose ambiguity. Vitamin K still requires careful coordination with medicines designed to block its action.

Who is it for
  • Adults seeking standalone MK-7
  • People who already obtain vitamin D separately
  • Users who prefer a vegetable capsule
Best for
  • Standalone vitamin K2 use
  • Customizing a separate bone-nutrient routine
  • Long-acting MK-7 supplementation

Pros

  • MK-7 form is identified
  • a substantial daily amount
  • Simple single-active formula
  • The single active is easy to understand but premium-priced

Cons

  • No vitamin D included
  • No calcium or magnesium included
  • supplied record repeats the same K2 amount and creates dose ambiguity

Warnings

  • Vitamin K can oppose warfarin and related vitamin-K-antagonist medicines; use requires consistent medical guidance.
  • People with a diagnosed bleeding or clotting disorder should not self-prescribe vitamin K2.
  • Standalone K2 should not be used to correct a diagnosed vitamin K deficiency without identifying the cause.

Nutrient quality

92 Highest impact

The focused active formula contains little apparent low-value padding. The ingredients generally fit the intended use despite a form or scope limitation.

Ingredient transparency

65 High impact

No named proprietary blend hides the core nutrients, though duplicated entries reduce clarity. A complete list of inactive ingredients is not supplied.

Customer satisfaction

86 Highest impact

The aggregate customer rating is strong. The modest review count limits confidence in the aggregate rating.

Value for money

71 High impact

The price is supported mainly by useful core actives rather than low-value extras. Serving value is weak relative to the disclosed active formula.

Report analysis

Goals

Anti-Aging
Anti-Aging
Impact
Highest effect
A- Goal FitA+ Strength of SupportB CoverageA+ Formula Quality
Vitamin K · 150 mcg

Vitamin K2 as menaquinone-7 supports activation of proteins involved in directing calcium toward bone and away from soft tissues. That mechanism is directly relevant to maintaining skeletal and vascular function with age.

The 150 mcg amount is meaningful, clearly disclosed, and uses a preferred long-acting K2 form. Vitamin K2 can interfere with warfarin and related vitamin K antagonist therapy by reducing the medication's anticoagulant effect.

Study evidence
Vitamin K Supportive 27 studies
Heart Health
Heart Health
Impact
Highest effect
A Goal FitA+ Strength of SupportC CoverageA+ Formula Quality
Vitamin K · 150 mcg

Menaquinone-7 directly supports vitamin K-dependent calcium handling and arterial health. The focused ingredient and substantial amount make it strongly aligned with the selected goal.

The form and amount are clearly disclosed in one capsule. Vitamin K can interfere with warfarin and related vitamin K antagonists, so users of those medicines need clinician-guided consistency.

Study evidence
Vitamin K Mixed 62 studies
Cardiovascular Support
Cardiovascular Support
Impact
Highest effect
B+ Goal FitA+ Strength of SupportC- CoverageA+ Formula Quality
Vitamin K · 150 mcg

Vitamin K2 as MK-7 directly supports healthy calcium placement in arteries and bones. The 150 mcg amount is substantial and fully disclosed.

The single-ingredient formula offers excellent depth in one vascular pathway but no lipid, blood-pressure, or rhythm support. Vitamin K2 can interfere with warfarin and other vitamin K antagonist treatment, so affected users need consistent intake and clinician-directed dosing.

Study evidence
Vitamin K Supportive 40 studies
Bone Health
Bone Health
Impact
Highest effect
A- Goal FitA Strength of SupportC- CoverageA+ Formula Quality
Vitamin K · 150 mcg

MK-7 directly supports osteocalcin, a protein that helps bind calcium into bone. The clearly disclosed serving provides a strong, focused amount for skeletal support.

The long-acting vitamin form is a major strength, although no calcium, vitamin D, or structural protein is included. MK-7 can counteract warfarin, so anticoagulant users need consistent intake and clinician-guided monitoring.

Study evidence
Vitamin K Supportive 78 studies
General Health
General Health
Impact
Highest effect
A- Goal FitA- Strength of SupportC CoverageA Formula Quality
Vitamin K · 150 mcg

MK-7 supports foundational calcium handling and long-term skeletal maintenance. The single vitamin focuses on calcium regulation rather than several general-health pillars.

The 150 mcg MK-7 amount is well aligned with common daily supplemental use. MK-7 can interfere with warfarin and related vitamin K antagonists, so users of those medicines need managed, consistent vitamin K intake.

Study evidence
Vitamin K Supportive 34 studies

Ingredients

IngredientAmount per serving
Vitamin K (Menaquinone-7, Vitamin K2)
 150 mcg
Adults 18–50
Report overview
Vitamin K (Menaquinone-7, Vitamin K2) · 150 mcg OverallScore71
C+ Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyF Value

The dedicated K2 formula provides MK-7 at a well-aligned amount for bone and cardiovascular support. Dry delivery without a lipid base may reduce absorption unless the serving is taken with dietary fat. The clinical MK-7 dose is useful, but the high cost lacks a branded source or added vitamin D3 to justify it. Vitamin K can counteract warfarin and other vitamin K antagonists, so users of those medicines should keep intake consistent and coordinate changes with their prescriber.

View ingredientView products
Loading alternative details
86 Performance

Liquid D-3 & MK-7

NOW
<p>Liquid delivery combines MK-7 with a substantial vitamin D3 amount and provides flexible dosing with strong bone- and heart-goal alignment. Added vitamin D broadens the formula but may be unnecessary when only standalone K2 is wanted. Vitamin K requires clinician-directed consistency with warfarin-type medicines.</p>
87 Performance

Vitamin D3 25 mcg (1000 IU) & K2 120 mcg

Natural Factors
<p>Moderate vitamin D3 and MK-7 create a balanced maintenance pairing in a softgel, with only minor ambiguity from duplicate K2 source entries. Added vitamin D broadens the formula but may be unnecessary when only standalone K2 is wanted. Vitamin K requires clinician-directed consistency with warfarin-type medicines.</p>
84 Performance

D3 + K2

Nature Made
<p>All-trans MK-7 and vitamin D3 use clearly defined forms in a focused softgel, improving active-form clarity. Added vitamin D broadens the formula but may be unnecessary when only standalone K2 is wanted. Vitamin K requires clinician-directed consistency with warfarin-type medicines.</p>
88 Budget

Vitamin K2 MK-7 100 mcg

Nutricost
<p>At a lower serving cost, a clearly stated MK-7 amount creates a simple, easy-to-assess vitamin K2 option, although the dry capsule has no stated lipid carrier. It preserves the original standalone K2 purpose without adding unnecessary vitamin D. Vitamin K can oppose warfarin-type anticoagulants.</p>
87 Budget

MK-7 Vitamin K-2 100 mcg

NOW
<p>At a lower serving cost, a meaningful long-acting MK-7 amount provides focused vitamin K2 support with a simple active formula. It preserves the original standalone K2 purpose without adding unnecessary vitamin D. Vitamin K can oppose warfarin-type anticoagulants.</p>
85 Budget

Vitamin K2 MenaQ7 100 mcg

AN Amazing Nutrition Amazing Formulas
<p>At a lower serving cost, natto-derived MenaQ7 provides a clearly identified long-acting vitamin K2 form in a focused formula. It preserves the original standalone K2 purpose without adding unnecessary vitamin D. Vitamin K can oppose warfarin-type anticoagulants.</p>
86 Value

Vitamin K2 100 mcg + Vitamin D3 125 mcg

Nutricost
<p>MK-7 and vitamin D3 provide a fully disclosed combination at very favorable serving value, but the vitamin D amount is concentrated. The standalone options avoid adding vitamin D, while combination choices are useful only when vitamin D is also wanted. Vitamin K can reduce the effect of warfarin-type anticoagulants.</p>
86 Value

Vitamins D3 2500 IU (62.5 mcg) & K2 120 mcg

NaturesPlus
<p>MK-7 and a substantial vitamin D3 amount provide focused bone and cardiovascular support at a low serving cost, though the dry tablet lacks a lipid carrier. The standalone options avoid adding vitamin D, while combination choices are useful only when vitamin D is also wanted. Vitamin K can reduce the effect of warfarin-type anticoagulants.</p>
86 Value

Natural Vitamin K2 MK-7 with MenaQ7 100 mcg

Doctor's Best
<p>Branded MenaQ7 provides a meaningful long-acting K2 amount with clear active disclosure and good serving value. The standalone options avoid adding vitamin D, while combination choices are useful only when vitamin D is also wanted. Vitamin K can reduce the effect of warfarin-type anticoagulants.</p>
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women.
    Knapen MH; Drummen NE; Smit E; Vermeer C; Theuwissen E · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014
    Randomized trial244 participantsBone Health forVitamin K
  2. Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials.
    Huang ZB; Wan SL; Lu YJ; Ning L; Liu C; Fan SW · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015
    Meta-analysis6,759 participants19 studies pooledBone Health forVitamin K
  3. Investigating the interrelationship of vitamin K and vitamin D status on bone density: results from the VITamin D and OmegA-3 TriaL.
    Chou SH; Booth SL; Cook NR; Kim E; Kotler G; Fu X; Buring JE; Manson JE; LeBoff MS · JBMR plus · 2026
    Randomized trial771 participantsBone Health forVitamin K
  4. Vitamin K Intake and Atherosclerotic Cardiovascular Disease in the Danish Diet Cancer and Health Study.
    Bellinge JW; Dalgaard F; Murray K; Connolly E; Blekkenhorst LC; Bondonno CP; Lewis JR; Sim M; Croft KD; Gislason G; Torp-Pedersen C; Tjønneland A; Overvad K; Hodgson JM; Schultz C; Bondonno NP · Journal of the American Heart Association · 2021
    Cohort study53,372 participantsCardiovascular Support Heart Health forVitamin K
  5. Association of vitamin K with cardiovascular events and all-cause mortality: a systematic review and meta-analysis.
    Chen HG; Sheng LT; Zhang YB; Cao AL; Lai YW; Kunutsor SK; Jiang L; Pan A · European journal of nutrition · 2020
    Meta-analysis222,592 participants21 studies pooledCardiovascular Support forVitamin K
  6. Circulating uncarboxylated matrix Gla protein, a marker of vitamin K status, as a risk factor of cardiovascular disease.
    van den Heuvel EG; van Schoor NM; Lips P; Magdeleyns EJ; Deeg DJ; Vermeer C; den Heijer M · Maturitas · 2014
    Cohort study577 participantsCardiovascular Support forVitamin K
  7. Vitamin K status, cardiovascular disease, and all-cause mortality: a participant-level meta-analysis of 3 US cohorts.
    Shea MK; Barger K; Booth SL; Matuszek G; Cushman M; Benjamin EJ; Kritchevsky SB; Weiner DE · The American journal of clinical nutrition · 2020
    Meta-analysis3,891 participants3 studies pooledAnti-Aging General Health forVitamin K
  8. Topical Menaquinone‑7 (Vitamin K2, MK-7) as a Mitochondrial Bioenergetic Activator for Skin Anti-Aging: Mechanistic Evidence in Skin Cells and a Randomized Split-Face/Neck Study.
    Huang H; Wei R; Xu C; Liu C; Zhao S; Li Y; Wang M · ACS omega · 2026
    Randomized trial30 participantsAnti-Aging forVitamin K
  9. Vitamin K status and cognitive function in healthy older adults.
    Presse N; Belleville S; Gaudreau P; Greenwood CE; Kergoat MJ; Morais JA; Payette H; Shatenstein B; Ferland G · Neurobiology of aging · 2014
    Cross-sectional study320 participantsAnti-Aging forVitamin K
  10. High dephospho-uncarboxylated matrix Gla protein concentrations, a plasma biomarker of vitamin K, in relation to frailty: the Longitudinal Aging Study Amsterdam.
    Machado-Fragua MD; Hoogendijk EO; Struijk EA; Rodriguez-Artalejo F; Lopez-Garcia E; Beulens JW; van Ballegooijen AJ · European journal of nutrition · 2021
    Cohort study644 participantsAnti-Aging forVitamin K
  11. Vitamin K Concentration and Cognitive Status in Elderly Patients on Anticoagulant Therapy: A Pilot Study.
    Alisi L; Cafolla C; Gentili A; Tartaglione S; Curini R; Cafolla A · Journal of aging research · 2022
    Cross-sectional study85 participantsAnti-Aging forVitamin K
  12. Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials.
    Cockayne S; Adamson J; Lanham-New S; Shearer MJ; Gilbody S; Torgerson DJ · Archives of internal medicine · 2006
    Meta-analysis13 studies pooledBone Health forVitamin K
  13. Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Ichimura S · Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association · 2001
    Randomized trial92 participantsBone Health forVitamin K
  14. Efficacy and safety of vitamin K2 for postmenopausal women with osteoporosis at a long-term follow-up: meta-analysis and systematic review.
    Zhou M; Han S; Zhang W; Wu D · Journal of bone and mineral metabolism · 2022
    Meta-analysis6,853 participants9 studies pooledBone Health forVitamin K
  15. Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women.
    Koitaya N; Sekiguchi M; Tousen Y; Nishide Y; Morita A; Yamauchi J; Gando Y; Miyachi M; Aoki M; Komatsu M; Watanabe F; Morishita K; Ishimi Y · Journal of bone and mineral metabolism · 2015
    Randomized trial48 participantsBone Health forVitamin K
  16. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial.
    Knapen MH; Braam LA; Drummen NE; Bekers O; Hoeks AP; Vermeer C · Thrombosis and haemostasis · 2016
    Randomized trial244 participantsCardiovascular Support Heart Health forVitamin K
  17. Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women.
    de Vries F; Bittner R; Maresz K; Machuron F; Gåserød O; Jeanne JF; Schurgers LJ · Nutrients · 2025
    Randomized trial165 participantsCardiovascular Support forVitamin K
  18. Dietary Vitamin K1 Intake and Incident Aortic Valve Stenosis.
    Schultz CJ; Dalgaard F; Bellinge JW; Murray K; Sim M; Connolly E; Blekkenhorst LC; Bondonno CP; Lewis JR; Gislason GH; Tjønneland A; Overvad K; Hodgson JM; Bondonno NP · Arteriosclerosis, thrombosis, and vascular biology · 2024
    Cohort study55,545 participantsCardiovascular Support Heart Health forVitamin K
  19. Association between vitamin K1 intake and mortality in the Danish Diet, Cancer, and Health cohort.
    Palmer CR; Bellinge JW; Dalgaard F; Sim M; Murray K; Connolly E; Blekkenhorst LC; Bondonno CP; Croft KD; Gislason G; Tjønneland A; Overvad K; Schultz C; Lewis JR; Hodgson JM; Bondonno NP · European journal of epidemiology · 2021
    Cohort study56,048 participantsCardiovascular Support Heart Health forVitamin K
  20. Dietary vitamin K intake associates with reduced all-cause mortality in non-alcoholic fatty liver disease patients.
    Huang Y; Zhu X; Han L; Hu H · Scientific reports · 2025
    Cohort study7,857 participantsGeneral Health forVitamin K
  21. The Effect of Topical Vitamin K1 on the Treatment of Cetuximab-Induced Skin Rashes in Metastatic Colorectal Cancer Patients.
    Roayaei M; Rezaei M; Najafizade N · Advanced biomedical research · 2024
    Randomized trial49 participantsGeneral Health forVitamin K
  22. Effect of vitamin K on improving post‑kidney transplant outcomes: a meta‑analysis.
    Sun Z; Zhu K; Liang G; Yan F; Chao S; Jia L; Niu Y · Experimental and therapeutic medicine · 2023
    Meta-analysis7 studies pooledGeneral Health forVitamin K
  23. Vitamin K1 intake is associated with lower risk for all-cause and cardiovascular disease mortality in community-dwelling older Australian women.
    Dupuy M; Radavelli-Bagatini S; Zhong L; Dalla Via J; Zhu K; Blekkenhorst LC; Bondonno NP; Linneberg A; Bellinge JW; Schultz C; Courtney W; Prince RL; Hodgson JM; Lewis JR; Sim M · Nutrition, metabolism, and cardiovascular diseases : NMCD · 2024
    Cohort study1,436 participantsGeneral Health forVitamin K
  24. The effect of vitamin K1 on arterial calcification activity in subjects with diabetes mellitus: a post hoc analysis of a double-blind, randomized, placebo-controlled trial.
    Bellinge JW; Francis RJ; Lee SC; Bondonno NP; Sim M; Lewis JR; Watts GF; Schultz CJ · The American journal of clinical nutrition · 2022
    Randomized trial149 participantsHeart Health forVitamin K